EUVIMEDEUVIMED entdecken
Open Access

Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease

Rachel Kohler, Dyann M Segvich, Olivia Reul, Corinne E Metzger, Matthew R Allen, Joseph M Wallace

Bone · 2025

DOI: 10.1016/j.bone.2025.117415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone, 2025. Verfasst von Rachel Kohler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Weldon School of Biomedical Engineering, Purdue University, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Raloxifene Hydrochloride, Antibodies, Monoclonal, Diabetic Nephropathies, Bone and Bones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIAMS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Comorbid diabetes and chronic kidney disease create a complex disease state with multi-faceted impacts on bone health, primarily reduced bone mass and tissue quality. To reduce fracture risk in this growing population, interventions are needed that target both bone mass and quality. Romosozumab (Romo) is an FDA-approved sclerostin inhibitor that has been shown to increase bone mass and strength in a murine model of combined diabetes and CKD (DKD), while Raloxifene (RAL) is a mild anti-resorptive used to treat osteoporosis that has also been shown to increase bone mechanical properties by increasing bone bound water content. We aimed to test whether combined RAL and Romo treatment could improve bone quality in our murine model of DKD more than either treatment alone. Using a previously established streptozotocin- and adenine-diet-induced model, male, C57BL/6J mice were randomly divided into four treatment groups and given daily subcutaneous injections of 100 μL vehicle (phosphorus buffered saline, PBS) or 0.5 mg/kg RAL. In addition, two groups were also given a weekly dose of Romo (10 mg/kg). Overall, Romo increased whole-bone strength and RAL improved tissue-level mechanical properties. Combined RAL-Romo treatment led to significantly higher cortical and trabecular bone mass compared to untreated controls. These morphological improvements created corresponding improvements in cortical bending strength and vertebral trabecular compression strength. These results suggest that combined RAL-Romo treatment provides both mass and quality improvements to DKD bone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Raloxifene HydrochlorideAntibodies, MonoclonalDiabetic NephropathiesBone and BonesAnimalsMaleDisease Models, AnimalMice, Inbred C57BLMiceBone DensityX-Ray MicrotomographyDrug Therapy, Combination

Stichwörter der Autor:innen

Bone qualityChronic kidney diseaseCombination treatmentDiabetesRaloxifeneRomosozumab

Substanzen

Raloxifene HydrochlorideromosozumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Weldon School of Biomedical Engineering, Purdue University, Indianapolis, IN, United States.
  • Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, United States.
  • Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, United States; Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States.
  • Weldon School of Biomedical Engineering, Purdue University, Indianapolis, IN, United States; Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States. Electronic address: jmwalla@iu.edu.

Förderung

  • BLRD VA
  • NIAMS NIH HHS
  • National Institutes of Health
  • U.S. Department of Veterans Affairs

Zitieren

APA

Kohler, R., Segvich, D. M., Reul, O., Metzger, C. E., Allen, M. R., & Wallace, J. M. (2025). Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease. Bone. https://doi.org/10.1016/j.bone.2025.117415

Vancouver

Kohler R, Segvich DM, Reul O, Metzger CE, Allen MR, Wallace JM. Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease. Bone. 2025. doi:10.1016/j.bone.2025.117415

BibTeX
@article{Kohler2025,
  author = {Kohler, Rachel and Segvich, Dyann M and Reul, Olivia and Metzger, Corinne E and Allen, Matthew R and Wallace, Joseph M},
  title = {Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease},
  journal = {Bone},
  year = {2025},
  doi = {10.1016/j.bone.2025.117415}
}
Kostenlos starten →